1. Quillen DA. Common causes of vision loss in elderly patients. Am Fam Physician. 1999 Jul;60(1):99-108.
2. Nolan JM, Stack J, O’ DO, Loane E, Beatty S. Risk factors for age-related maculopathy are associated with a relative lack of macular pigment. Exp Eye Res. 2007 Jan;84(1):61-74.
3. No authors listed. Lutein and zeaxanthin. Monograph. Altern Med Rev. 2005 Jun;10(2):128-35.
4. Delcourt C, Carriere I, Delage M, Barberger-Gateau P, Schalch W. Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA Study. Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2329-35.
5. Zhang J, Dhakal I, Stone A, et al. Plasma carotenoids and prostate cancer: a population-based case-control study in Arkansas. Nutr Cancer. 2007;59(1):46-53.
6. Lidebjer C, Leanderson P, Ernerudh J, Jonasson L. Low plasma levels of oxygenated carotenoids in patients with coronary artery disease. Nutr Metab Cardiovasc Dis. 2007 Jul;17(6):448-56.
7. Akbaraly NT, Faure H, Gourlet V, Favier A, Berr C. Plasma carotenoid levels and cognitive performance in an elderly population: results of the EVA Study. J Gerontol A Biol Sci Med Sci. 2007 Mar;62(3):308-16.
8. Bressler NM. Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract. 2002 Mar;15(2):142-52.
9. Patel M, Chan CC. Immunopathological aspects of age-related macular degeneration. Semin Immunopathol. 2008 Feb 26.
10. Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA. 1994 Nov 9;272(18):1413-20.
11. Whitehead AJ, Mares JA, Danis RP. Macular pigment: a review of current knowledge. Arch Ophthalmol. 2006 Jul;124(7):1038-45.
12. Bandello F, Augustin A, Sahel JA, et al. Association between Visual Acuity and Medical and Non-Medical Costs in Patients with Wet Age-Related Macular Degeneration in France, Germany and Italy. Drugs Aging. 2008;25(3):255-68.
13. Chitchumroonchokchai C, Bomser JA, Glamm JE, Failla ML. Xanthophylls and alpha-tocopherol decrease UVB-induced lipid peroxidation and stress signaling in human lens epithelial cells. J Nutr. 2004 Dec;134(12):3225-32.
14. Meyer CH, Sekundo W. Nutritional supplementation to prevent cataract formation. Dev Ophthalmol. 2005;38:103-19.
15. Morris D, Fraser SG, Gray C. Cataract surgery and quality of life implications. Clin Interv Aging. 2007;2(1):105-8.
16. Lucarini M, Lanzi S, D’Evoli L, Aguzzi A, Lombardi-Boccia G. Intake of vitamin A and carotenoids from the Italian population--results of an Italian total diet study. Int J Vitam Nutr Res. 2006 May;76(3):103-9.
17. Krinsky NI, Johnson EJ. Carotenoid actions and their relation to health and disease. Mol Aspects Med. 2005 Dec;26(6):459-516.
18. Garcia-Closas R, Berenguer A, Jose TM, et al. Dietary sources of vitamin C, vitamin E and specific carotenoids in Spain. Br J Nutr. 2004 Jun;91(6):1005-11.
19. Bone RA, Landrum JT, Alvarez-Correa C, Etienne V, Ruiz CA. Macular Pigment and Serum Response to Dietary Supplementation with Meso-zeaxanthin. Annual meeting of ARVO. May 4, 2003; Fort Lauderdale, FL: Abstract 405/B380.
20. Bone RA, Landrum JT, Hime GW, Cains A, Zamor J. Stereochemistry of the human macular carotenoids. Invest Ophthalmol Vis Sci. 1993 May;34(6):2033-40.
21. Ribaya-Mercado JD, Blumberg JB. Lutein and zeaxanthin and their potential roles in disease prevention. J Am Coll Nutr. 2004 Dec;23(6 Suppl):567S-87S.
22. Delcourt C. Application of nutrigenomics in eye health. Forum Nutr. 2007;60:168-75.
23. Ahmed SS, Lott MN, Marcus DM. The macular xanthophylls. Surv Ophthalmol. 2005 Mar;50(2):183-93.
24. Matuszak Z, Bilska MA, Reszka KJ, Chignell CF, Bilski P. Interaction of singlet molecular oxygen with melatonin and related indoles. Photochem Photobiol. 2003 Nov;78(5):449-55.
25. Bone RA, Landrum JT, Guerra LH, Ruiz CA. Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. J Nutr. 2003 Apr;133(4):992-8.
26. Siems WG, Sommerburg O, van Kuijk FJ. Lycopene and beta-carotene decompose more rapidly than lutein and zeaxanthin upon exposure to various pro-oxidants in vitro. Biofactors. 1999;10(2-3):105-13.
27. Trevithick-Sutton CC, Foote CS, Collins M, Trevithick JR. The retinal carotenoids zeaxanthin and lutein scavenge superoxide and hydroxyl radicals: a chemiluminescence and ESR study. Mol Vis. 2006;12:1127-35.
28. O’Connell ED, Nolan JM, Stack J, et al. Diet and risk factors for age-related maculopathy. Am J Clin Nutr. 2008 Mar;87(3):712-22.
29. Moeller SM, Voland R, Tinker L, et al. Associations Between Age-Related Nuclear Cataract and Lutein and Zeaxanthin in the Diet and Serum in the Carotenoids in the Age-Related Eye Disease Study (CAREDS), an Ancillary Study of the Women’s Health Initiative. Arch Ophthalmol. 2008 Mar;126(3):354-64.
30. SanGiovanni JP, Chew EY, Clemons TE, et al. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol. 2007 Sep;125(9):1225-32.
31. Rodriguez-Rodriguez E, Ortega RM, Lopez-Sobaler AM, et al. The relationship between antioxidant nutrient intake and cataracts in older people. Int J Vitam Nutr Res. 2006 Nov;76(6):359-66.
32. Vu HT, Robman L, Hodge A, McCarty CA, Taylor HR. Lutein and zeaxanthin and the risk of cataract: the Melbourne visual impairment project. Invest Ophthalmol Vis Sci. 2006 Sep;47(9):3783-6.
33. Christen WG, Liu S, Glynn RJ, Gaziano JM, Buring JE. Dietary carotenoids, vitamins C and E, and risk of cataract in women: a prospective study. Arch Ophthalmol. 2008 Jan;126(1):102-9.
34. Dagnelie G, Zorge IS, McDonald TM. Lutein improves visual function in some patients with retinal degeneration: a pilot study via the Internet. Optometry. 2000 Mar;71(3):147-64.
35. Khachik F, de Moura FF, Chew EY, et al. The effect of lutein and zeaxanthin supplementation on metabolites of these carotenoids in the serum of persons aged 60 or older. Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5234-42.
36. Trieschmann M, Beatty S, Nolan JM, et al. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. Exp Eye Res. 2007 Apr;84(4):718-28.
37. Stringham JM, Hammond BR. Macular pigment and visual performance under glare conditions. Optom Vis Sci. 2008 Feb;85(2):82-8.
38. Falsini B, Piccardi M, Iarossi G, et al. Influence of short-term antioxidant supplementation on macular function in age-related maculopathy: a pilot study including electrophysiologic assessment. Ophthalmology. 2003 Jan;110(1):51-60.
39. Richer S, Stiles W, Statkute L, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry. 2004 Apr;75(4):216-30.
40. Richer S, Devenport J, Lang JC. LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry. 2007 May;78(5):213-9.
41. Schalch W, Cohn W, Barker FM, et al. Xanthophyll accumulation in the human retina during supplementation with lutein or zeaxanthin - the LUXEA (LUtein Xanthophyll Eye Accumulation) study. Arch Biochem Biophys. 2007 Feb 15;458(2):128-35.
42. Parisi V, Tedeschi M, Gallinaro G, et al. Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year. Ophthalmology. 2008 Feb;115(2):324-33.
43. Cangemi FE. TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD. BMC Ophthalmol. 2007;73.
44. Sun Z, Yao H. The influence of di-acetylation of the hydroxyl groups on the anti-tumor-proliferation activity of lutein and zeaxanthin. Asia Pac J Clin Nutr. 2007;16 Suppl 1:447-52.
45. Astner S, Wu A, Chen J, et al. Dietary lutein/zeaxanthin partially reduces photoaging and photocarcinogenesis in chronically UVB-irradiated Skh-1 hairless mice. Skin Pharmacol Physiol. 2007;20(6):283-91.
46. Palombo P, Fabrizi G, Ruocco V, et al. Beneficial long-term effects of combined oral/topical antioxidant treatment with the carotenoids lutein and zeaxanthin on human skin: a double-blind, placebo-controlled study. Skin Pharmacol Physiol. 2007;20(4):199-210.
47. Hold GL, El-Omar ME. Genetic aspects of inflammation and cancer. Biochem J. 2008 Mar 1;410(2):225-35.
48. Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr Rev. 2007 Dec;65(12 Pt 2):S140-6.
49. Zhang M, Holman CD, Binns CW. Intake of specific carotenoids and the risk of epithelial ovarian cancer. Br J Nutr. 2007 Jul;98(1):187-93.
50. Berr C, Richard MJ, Roussel AM, Bonithon-Kopp C. Systemic oxidative stress and cognitive performance in the population-based EVA study. Etude du Vieillissement Arteriel. Free Radic Biol Med. 1998 May;24(7-8):1202-8.
51. Berr C, Balansard B, Arnaud J, Roussel AM, Alperovitch A. Cognitive decline is associated with systemic oxidative stress: the EVA study. Etude du Vieillissement Arteriel. J Am Geriatr Soc. 2000 Oct;48(10):1285-91.
52. Hozawa A, Jacobs DR Jr, Steffes MW, Gross MD, Steffen LM, Lee DH. Relationships of circulating carotenoid concentrations with several markers of inflammation, oxidative stress, and endothelial dysfunction: the Coronary Artery Risk Development in Young Adults (CARDIA)/Young Adult Longitudinal Trends in Antioxidants (YALTA) study. Clin Chem. 2007 Mar;53(3):447-55.